Dyne Therapeutics CFO Sells Shares
Erick Lucera, CFO of Dyne Therapeutics, sold shares worth $48,114.
Key Points
- Erick Lucera, CFO of Dyne Therapeutics, sold 2,362 shares on June 25, 2026, at an average price of $20.37, totaling $48,114.
- Dyne Therapeutics, Inc. has a market cap of $3.46 billion and a 52-week range between $8.06 and $25.00.
- Analysts maintain a strong buy consensus with a mean target price of $38.25, based on 16 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Erick Lucera, the Chief Financial Officer of Dyne Therapeutics, Inc. (NasdaqGS: DYN), sold 2,362 shares of the company on June 25, 2026. The shares were sold at an average price of $20.37, amounting to a total transaction value of $48,113.94. This sale was not part of a pre-scheduled trading plan.
Insider Buying and Selling at Dyne Therapeutics, Inc.
The recent insider activity at Dyne Therapeutics included Erick Lucera's sale of 2,362 shares on June 25, 2026, at $20.37 each. Additionally, Jason Rhodes, in multiple transactions, sold shares on June 23, 24, and 25, 2026, at prices around $21.00, all under pre-planned trading agreements. Dirk Kersten also sold shares on June 22 and 23, 2026, as part of planned sales.
Other Institutional Activity in Dyne Therapeutics
T. Rowe Price Investment Management, Inc. increased its holdings in Dyne Therapeutics by 13,245,712 shares, bringing its total to 30,785,801 shares, valued at approximately $558.1 million. Janus Henderson Group PLC reduced its stake by 240,346 shares, ending with 13,647,376 shares worth about $247.4 million. BlackRock, Inc. added 509,032 shares to its holdings, now owning 11,699,870 shares valued at $212.1 million. FMR LLC boosted its position by 2,339,059 shares, holding 8,908,980 shares worth roughly $161.5 million. Orbis Allan Gray Ltd increased its stake by 1,960,303 shares, totaling 6,762,231 shares valued at $122.6 million.
Dyne Therapeutics, Inc. Stock Down 16.5%
Shares of Dyne Therapeutics traded near $20.94 on Saturday. The company has a market cap of approximately $3.46 billion. It operates with a forward P/E ratio of -7.02, indicating it is not currently profitable. The stock's 52-week range is between $8.06 and $25.00, with a 50-day moving average of $18.41 and a 200-day moving average of $17.85. Dyne Therapeutics maintains a strong liquidity position with a current ratio of 19.92 and a quick ratio of 18.97.
$DYN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 15, 2026, Evercore ISI Group maintained its buy rating for Dyne Therapeutics, setting a price target of $33.00. Bernstein also maintained a hold rating with a target of $24.00 on May 13, 2026. The consensus among analysts is a strong buy, with a mean target price of $38.25 based on 16 analyst opinions.
About Dyne Therapeutics
Dyne Therapeutics, Inc. is a biotech company based in Waltham, Massachusetts, focusing on developing treatments for neuromuscular diseases. Founded in 2017, the company is working on therapies for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and other muscle-related diseases using its FORCE platform. Dyne is led by CEO John G. Cox and employs about 263 people.
Bottom Line
Erick Lucera's recent sale of Dyne Therapeutics shares is part of ongoing insider transactions. The company, known for its focus on neuromuscular disease treatments, continues to attract institutional interest, evidenced by significant activity from major investment firms. Analyst sentiment remains positive, with a strong buy consensus and a mean price target suggesting potential future growth.
Get Dyne Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DYN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.